Cytori Loses Bid to Overturn FDA Bar on Stem-Cell Devices

Cytori Therapeutics Inc., a biotechnology company developing experimental burn treatment therapies, lost a U.S. appeals court bid to overturn the Food and Drug Administration’s initial rejection of two medical devices that use fat as a source of stem-cell therapy.

The U.S. Court of Appeals in Washington upheld the FDA’s decision that two devices submitted by Cytori for approval required more extensive testing before they could be released safely on the market.